Process of making somatostatin modulators
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
1. A method of treating acromegaly or a neuroendocrine tumor, or combination thereof, in a human comprising orally administering to the human with acromegaly or a neuroendocrine tumor, or combination thereof, a pharmaceutical composition comprising the compound 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof; and at least one pharmaceutically acceptable excipient, wherein 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof is crystalline and is characterized as having: an X-ray powder diffraction (XRPD) pattern with peaks at 4.5° 2-Theta, 9.1° 2-Theta, 10.2° 2-Theta, 16.3° 2-Theta, 18.4° 2-Theta, and 19.1° 2-Theta; an X-ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 1 ; a Differential Scanning calorimetry (DSC) thermogram with an endotherm having an onset at about 207° C. and a peak at about 220° C.; a Differential Scanning calorimetry (DSC) thermogram substantially the same as shown in FIG. 2( a ) ; an infrared (IR) spectrum with peaks at 2223 cm −1 , 1620 cm −1 , 1595 cm −1 , 1457 cm −1 , 1238 cm −1 , 1220 cm −1 , and 1117 cm −1 ; an infrared (IR) spectrum substantially the same as shown in FIG. 3 ; an unchanged XRPD when heated up to about 200° C., upon exposure to more than 90% relative humidity for about 24 hours, or upon exposure to about 75% RH and 40° C. over one week, or combinations thereof; or combinations thereof.
2. The method of claim 1 , wherein the pharmaceutical composition comprises 1-100 mg of 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof.
3. The method of claim 1 , wherein the pharmaceutical composition is orally administered to the human once a day.
4. The method of claim 1 , wherein the pharmaceutical composition is in the form of a solid form pharmaceutical composition.
5. The method of claim 1 , wherein the pharmaceutical composition is in the form of a capsule.
6. The method of claim 5 , wherein the capsule is orally administered to the human once a day.
7. The method of claim 1 , wherein the pharmaceutical composition is in the form of a capsule and comprises 10 mg of 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, or solvate thereof.
8. The method of claim 7 , wherein the capsule is orally administered to the human once a day.
9. The method of claim 1 , wherein the pharmaceutical composition is in the form of a tablet.
10. The method of claim 9 , wherein the tablet is orally administered to the human once a day.